Josefa Alvarez-Fuentes

List of Publications by Year
in descending order

42 papers	939 citations	361413 20 h-index	454955 30 g-index
42 all docs	42 docs citations	42 times ranked	1233 citing authors

#	Article	IF	Citations
1	Synthesis of lidocaine-loaded PLGA microparticles by flow focusing. International Journal of Pharmaceutics, 2008, 358, 27-35.	5.2	73
2	Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. International Journal of Pharmaceutics, 2002, 237, 107-118.	5.2	69
3	Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. International Journal of Pharmaceutics, 2002, 234, 213-221.	5.2	47
4	Diclofenac salts. I. fractal and thermal analysis of sodium and potassium diclofenac salts. Journal of Pharmaceutical Sciences, 2001, 90, 2049-2057.	3.3	46
5	In vitro and in vivo evaluation of Î”9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy. International Journal of Pharmaceutics, 2015, 487, 205-212.	5.2	44
6	Development of Enteric-coated Timed-release Matrix Tablets for Colon Targeting. Journal of Drug Targeting, 2004, 12, 607-612.	4.4	43
7	Nanostructures for Drug Delivery to the Brain. Current Medicinal Chemistry, 2011, 18, 5303-5321.	2.4	43
8	Drug Targeting to Cancer by Nanoparticles Surface Functionalized with Special Biomolecules. Current Medicinal Chemistry, 2012, 19, 3188-3195.	2.4	43
9	Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. International Journal of Nanomedicine, 2012, 7, 5793.	6.7	39
10	Insulin-loaded PLGA microparticles: flow focusingversusdouble emulsion/solvent evaporation. Journal of Microencapsulation, 2011, 28, 430-441.	2.8	37
11	Enhanced Cellular Uptake and Biodistribution of a Synthetic Cannabinoid Loaded in Surface-Modified Poly(lactic-co-glycolic acid) Nanoparticles. Journal of Biomedical Nanotechnology, 2014, 10, 1068-1079.	1.1	37
12	Design of controlled release inert matrices of naltrexone hydrochloride based on percolation concepts. International Journal of Pharmaceutics, 1999, 181, 23-30.	5.2	32
13	Communications Simultaneous Hplc Determination of some Drugs Commonly Used in Cold Medications: Dextromethorphan, Dephenhydramine, Phenylephrine, Phenylpropanolamine and Pseudoephedrine. Drug Development and Industrial Pharmacy, 1995, 21, 605-613.	2.0	29
14	Protein-loaded PLGA microparticles engineered by flow focusing: Physicochemical characterization and protein detection by reversed-phase HPLC. International Journal of Pharmaceutics, 2009, 380, 147-154.	5.2	28
15	Physical characterization of carteolol: EudragitÂ® L binding interaction. International Journal of Pharmaceutics, 1995, 114, 13-21.	5.2	23
16	Engineering of Î” 9 -tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. Colloids and Surfaces B: Biointerfaces, 2014, 123, 114-122.	5.0	23
17	Influence of diluents and manufacturing method on the in vitro dissolution of carteolol hydrochloride matrix tablets. International Journal of Pharmaceutics, 1995, 118, 151-160.	5.2	22
18	Development and in vitro evaluation of a controlled release formulation to produce wide dose interval morphine tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 544-549.	4.3	22

#	Article	IF	Citations
19	Role of Nanotechnology for Enzyme Replacement Therapy in Lysosomal Diseases. A Focus on Gaucherâ€™s Disease. Current Medicinal Chemistry, 2016, 23, 929-952.	2.4	22
20	Study of morphine hydrochloride percolation threshold in EudragitÂ® RSâ€“PM matrices. International Journal of Pharmaceutics, 1998, 170, 169-177.	5.2	21
21	Evaluation of EudragitÂ® RS-PO and EthocelÂ® 100 Matrices for the Controlled Release of Lobenzarit Disodium. Drug Development and Industrial Pharmacy, 1999, 25, 229-233.	2.0	20
22	Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer. Current Drug Targets, 2011, 12, 1096-1111.	2.1	20
23	Elaboration and â€œIn Vitroâ€•Characterization of 5-ASA Beads. Drug Development and Industrial Pharmacy, 2005, 31, 231-239.	2.0	18
24	Morphine Polymeric Coprecipitates for Controlled Release: Elaboration and Characterization. Drug Development and Industrial Pharmacy, 1994, 20, 2409-2424.	2.0	16
25	Neuroprotective effect of cannabinoids nanoplatforms in neurodegenerative diseases. Journal of Drug Delivery Science and Technology, 2017, 42, 84-93.	3.0	16
26	Diclofenac Salts. III. Alkaline and Earth Alkaline Salts. Journal of Pharmaceutical Sciences, 2005, 94, 2416-2431.	3.3	15
27	Receptor-targeted nanoparticles modulate cannabinoid anticancer activity through delayed cell internalization. Scientific Reports, 2022, 12, 1297.	3.3	13
28	Validation study of the conductometrical analysis. Application to the drug release studies from controlled release systems. Journal of Pharmaceutical and Biomedical Analysis, 1998, 18, 281-285.	2.8	10
29	Preclinical study of a controlled release oral morphine system in rats. International Journal of Pharmaceutics, 1996, 139, 237-241.	5.2	9
30	EudragitÂ® RS-PM and EthocelÂ® 100 Premium: influence over the behavior of didanosine inert matrix system. Il Farmaco, 2002, 57, 649-656.	0.9	9
31	Characterization of modified paracetamol by means of SEM and fractal analysis. International Journal of Pharmaceutics, 1996, 142, 143-151.	5.2	8
32	Study of a complexation process between naltrexone and EudragitÂ® L as an oral controlled release system. International Journal of Pharmaceutics, 1997, 148, 219-230.	5.2	8
33	In vitro evaluation of a morphine polymeric complex: Flowability behavior and dissolution study. AAPS PharmSciTech, 2004, 5, 23-29.	3.3	8
34	Development and Validation of an RP-HPLC Method for CB13 Evaluation in Several PLGA Nanoparticle Systems. Scientific World Journal, The, 2012, 2012, 1-9.	2.1	8
35	Use of Flow FocusingÂ® Technology to Produce Tobramycin-Loaded Plga Microparticles for Pulmonary Drug Delivery. Medicinal Chemistry, 2012, 8, 533-540.	1.5	6
36	Dehydration and rehydration of a hydrate diclofenac salt at room temperature. International Journal of Pharmaceutics, 1999, 181, 11-21.	5.2	4

#	Article	IF	Citations
37	Influence of the pH Value of the Dissolution Medium on the Release Profiles of a Morphine Polymeric Complex. Drug Development and Industrial Pharmacy, 1997, 23, 553-559.	2.0	3
38	Role of the electrokinetic properties on the stability of mebendazole suspensions for veterinary applications. International Journal of Pharmaceutics, 2010, 393, 162-167.	5.2	3
39	Effectiveness of repeated administration of a new oral naltrexone controlled-release system on morphine analgesia. Journal of Pharmacy and Pharmacology, 2010, 53, 1201-1205.	2.4	2
40	Influence of the Disintegrant on the Drug Percolation Threshold in Tablets. Drug Development and Industrial Pharmacy, 1997, 23, 665-669.	2.0	0
41	In vitro and in vivo Studies of a New Sustained Release Formulation of Morphine. Arzneimittelforschung, 2008, 58, 647-652.	0.4	0
42	Peroral Polyester Drug Delivery Systems. , 2016, , 243-289.		0